

Eansor Norman David  
 Form 4  
 August 09, 2018

**FORM 4**

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
 Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287  
 Expires: January 31, 2015  
 Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
 Eansor Norman David

2. Issuer Name and Ticker or Trading Symbol  
 BIO-TECHNE Corp [TECH]

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

(Last) (First) (Middle)  
 8100 SOUTHPARK WAY, A-8  
 (Street)

3. Date of Earliest Transaction (Month/Day/Year)  
 08/07/2018

\_\_\_\_ Director \_\_\_\_\_ 10% Owner  
 \_\_\_\_ Officer (give title below) \_\_\_\_ Other (specify below)

SVP - Novus Biologicals

LITTLETON, CO 80120

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)  
 \_X\_ Form filed by One Reporting Person  
 \_\_\_ Form filed by More than One Reporting Person

(City) (State) (Zip)

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
				(A) or (D)	Price		
Common Stock	08/07/2018		M	1,199 A	\$ 0	3,465	D
Common Stock	08/07/2018		F	348 D	\$ 180.14	3,117	D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

SEC 1474 (9-02)

Edgar Filing: Eansor Norman David - Form 4

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned**  
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)	Amount or Number of Shares
				Code	V (A) (D)	Date Exercisable	Expiration Date	Title	
Restricted Stock Units	(1)	08/07/2018		M		1,199	(2) (2)	Common Stock	1,199
Restricted Stock Units	(1)	08/07/2018		D		301	(2) (2)	Common Stock	301
Stock Options (Right to buy)	\$ 108.49	08/07/2018		D		1,881	(3) 08/07/2022	Common Stock	1,881
Restricted Stock Units	(1)	08/08/2018		A		2,537	(4) (4)	Common Stock	2,537
Stock Options (Right to buy)	\$ 177.32	08/08/2018		A		18,066	(5) 08/08/2025	Common Stock	18,066
Stock Options (Right to buy)	\$ 177.32	08/08/2018		A		13,550	(4) 08/08/2025	Common Stock	13,550
Restricted Stock Units	(1)						(6) (6)	Common Stock	2,280
Restricted Stock Units	(1)						(7) (7)	Common Stock	2,170
Stock Option (Right to Buy)	\$ 108.49						(8) 08/07/2022	Common Stock	12,500
Stock Option (Right to	\$ 94.35						(9) 08/12/2021	Common Stock	15,000

Buy)

Stock

Options  
(Right to  
buy)

\$ 125.05

(7)

08/09/2024

Common  
Stock

11,9

Stock

Options  
(Right to  
buy)

\$ 125.05

(10)

08/09/2024

Common  
Stock

15,9

Stock

Options  
(Right to  
buy)

\$ 106.59

(11)

08/18/2023

Common  
Stock

18,8

Stock

Options  
(Right to  
buy)

\$ 106.59

(6)

08/18/2023

Common  
Stock

14,1

## Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Eansor Norman David 8100 SOUTHPARK WAY, A-8 LITTLETON, CO 80120			SVP - Novus Biologicals	

## Signatures

/s/ Brenda S. Furlow, attorney in fact for N. David Eansor pursuant to Power of Attorney  
previously filed

08/09/2018

\_\_Signature of Reporting Person

Date

## Explanation of Responses:

- \* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock.
- (2) On 8/7/2018, the Board of Directors authorized discretionary vesting for 1,199 performance RSUs. The remainder of the performance RSUs were forfeited.
- (3) On 8/7/2018, the Board of Directors authorized discretionary vesting for 7,494 performance options. The remainder of the performance options were forfeited.
- (4) Vests in full or in part on 8/8/2021 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
- (5) Vests 4,517 shares each on 8/8/2019, 8/8/2020 and 4,516 shares each on 8/8/2021, 8/8/2022.
- (6) Vests in full or in part on 8/18/19 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
- (7)

## Edgar Filing: Eansor Norman David - Form 4

Vests in full or in part on 8/9/2020 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).

- (8) 3,125 shares vest on each of 8/7/16, 8/7/17, 8/7/18 and 8/7/19.
- (9) 3,750 shares vest on each of 8/12/15, 8/12/16, 8/12/17 and 8/12/18.
- (10) Vest 3,994 shares on each 8/9/2018, 8/9/2019, 8/9/2020, 8/9/2021
- (11) Vests 4,705 shares on 8/18/17, 8/18/18, and 8/18/19 and 4,704 shares on 8/18/20.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.